Physician profile
Derek S Larson
NPI 1588820096
$604,986.98
in general payments reported to CMS, 2019-2025
20 companies · $45K in 2025
The $45K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $46K · 2021: $98K · 2022: $99K · 2023: $142K · 2024: $139K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $243K · Travel and Lodging: $32K · Consulting Fee: $29K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,600 · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $243,400.00 |
| Travel and Lodging | $32,013.52 |
| Consulting Fee | $28,788.50 |
| Food and Beverage | $12,038.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,600.00 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $493,625.78 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $95,177.16 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $10,431.11 | 2022-2025 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $4,077.24 | 2019-2025 | Korsuva, Veltassa |
| C. R. Bard, INC. & Subsidiaries | $326.67 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $303.22 | 2022-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $150.25 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $137.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $133.52 | 2023-2025 | |
| Amgen INC. | $123.46 | 2019-2025 | Krystexxa |
| Glaxosmithkline, LLC. | $90.00 | 2022 | |
| Mallinckrodt Enterprises LLC | $76.99 | 2019 | |
| Ardelyx, INC. | $43.12 | 2024 | Ibsrela |
| Baxter Healthcare | $26.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.90 | 2025 | Jardiance |
| Cycle Pharmaceuticals INC | $19.88 | 2024 | Tiopronin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.71 | 2024 | |
| Biobeat USA INC. | $15.58 | 2024 | Bb-613 Bpm Kit |
| Aurinia Pharma U.S., INC. | $14.49 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.